display Latest news from Moffitt Cancer Center on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/moffitt-researchers-reveal-key-lag3-mechanisms-that-could-transform-cancer-immunotherapy/?sc=rsin /articles/moffitt-researchers-reveal-key-lag3-mechanisms-that-could-transform-cancer-immunotherapy/?sc=rsin Wed, 04 Sep 2024 11:00:50 EST Immune checkpoint inhibitors are a type of cancer treatment that helps the immune system attack cancer cells more effectively. One of the key proteins involved in this process is Lymphocyte Activation Gene-3 (LAG3), which suppresses the antitumor immune response. Moffitt Cancer Center /articles/moffitt-researchers-develop-new-chemical-method-to-enhance-drug-discovery/?sc=rsin /articles/moffitt-researchers-develop-new-chemical-method-to-enhance-drug-discovery/?sc=rsin Fri, 16 Aug 2024 10:05:29 EST Moffitt Cancer Center researchers have developed a novel reagent that enhances the precision of drug synthesis. This innovative method, published in Nature Communications, introduces a new sulfur fluoride exchange (SuFEx) reagent that allows for highly controlled production of crucial sulfur-based molecules, including sulfinamides, sulfonimidamides and sulfoximines. Moffitt Cancer Center /articles/moffitt-consortium-study-answers-questions-about-long-term-survivorship-following-car-t-treatment/?sc=rsin /articles/moffitt-consortium-study-answers-questions-about-long-term-survivorship-following-car-t-treatment/?sc=rsin Mon, 05 Aug 2024 08:05:00 EST Axicabtagene ciloleucel, commonly known as axi-cel, is an innovative immunotherapy that uses modified T cells to target and destroy cancer cells. Approved for patients who have not responded to at least two prior lines of therapy, axicabtagene ciloleucel has been a game-changer in treating large B-cell lymphoma. Moffitt Cancer Center /articles/new-moffitt-study-explores-how-antifragility-could-revolutionize-cancer-treatment/?sc=rsin /articles/new-moffitt-study-explores-how-antifragility-could-revolutionize-cancer-treatment/?sc=rsin Thu, 01 Aug 2024 09:05:17 EST In a new study published in npj Complexity, Moffitt Cancer Center researchers offer a new perspective on antifragility, proposing a unified framework for understanding the property across different complex systems. Moffitt Cancer Center /articles/moffitt-study-uncovers-key-immune-cells-for-combating-aggressive-merkel-cell-carcinoma/?sc=rsin /articles/moffitt-study-uncovers-key-immune-cells-for-combating-aggressive-merkel-cell-carcinoma/?sc=rsin Fri, 26 Jul 2024 09:05:46 EST A new study published today in Cancer Discovery is providing insights into why some Merkel cell carcinoma patients respond to this type of immunotherapy while others do not. Moffitt Cancer Center /articles/tumor-infiltrating-lymphocyte-therapy-marks-a-milestone-in-cancer-treatment/?sc=rsin /articles/tumor-infiltrating-lymphocyte-therapy-marks-a-milestone-in-cancer-treatment/?sc=rsin Thu, 18 Jul 2024 14:05:52 EST In a new commentary published in Cancer Cell, Moffitt Cancer Center scientists provide a comprehensive overview of the therapy's development and highlight its transformative potential. Moffitt Cancer Center /articles/moffitt-researchers-develop-synthesis-method-to-enhance-access-to-cancer-fighting-withanolides/?sc=rsin /articles/moffitt-researchers-develop-synthesis-method-to-enhance-access-to-cancer-fighting-withanolides/?sc=rsin Fri, 28 Jun 2024 14:05:43 EST Moffitt Cancer Center researchers have developed a groundbreaking method for the scalable synthesis of withanolides. Moffitt Cancer Center /articles/revolutionizing-ovarian-cancer-treatment-with-adaptive-parp-inhibitor-therapy/?sc=rsin /articles/revolutionizing-ovarian-cancer-treatment-with-adaptive-parp-inhibitor-therapy/?sc=rsin Wed, 26 Jun 2024 13:05:02 EST A new study led by researchers at Moffitt Cancer Center introduces an adaptive therapy approach that could optimize PARP inhibitor maintenance therapy, offering a more personalized and potentially less toxic treatment option for patients. Their work is featured as the cover article of the June 19 issue of Cell Systems. Moffitt Cancer Center /articles/moffitt-study-reveals-new-mechanism-of-drug-resistance-in-melanoma-leptomeningeal-disease/?sc=rsin /articles/moffitt-study-reveals-new-mechanism-of-drug-resistance-in-melanoma-leptomeningeal-disease/?sc=rsin Tue, 11 Jun 2024 11:05:58 EST Leptomeningeal disease is a rare but lethal complication faced by late-stage melanoma patients. It occurs when cancer cells spread to the membranes covering the brain and spinal cord, or the leptomeninges. This condition, which affects 5% to 8% of melanoma patients, often leads to rapid deterioration and is notoriously resistant to therapies. However, a new Moffitt Cancer Center study, published today in Cell Reports Medicine, uncovers the mechanisms that drive this drug resistance, offering new avenues for potential treatments. Moffitt Cancer Center /articles/engineering-cancer-s-end-moffitt-scientists-say-bioengineering-will-change-our-ability-to-research-and-treat-cancer/?sc=rsin /articles/engineering-cancer-s-end-moffitt-scientists-say-bioengineering-will-change-our-ability-to-research-and-treat-cancer/?sc=rsin Fri, 07 Jun 2024 08:05:38 EST Bioengineering is revolutionizing cancer research, and Moffitt Cancer Center is at the forefront of this transformative movement. Moffitt is the first National Cancer Institute-designated comprehensive cancer center with a dedicated bioengineering department. This area of science integrates engineering and physical sciences with oncology to change how we understand and treat this complex disease. Moffitt Cancer Center /articles/innovative-combination-therapy-shows-promise-for-bladder-cancer-patients-unresponsive-to-standard-treatment/?sc=rsin /articles/innovative-combination-therapy-shows-promise-for-bladder-cancer-patients-unresponsive-to-standard-treatment/?sc=rsin Thu, 06 Jun 2024 09:05:19 EST In a groundbreaking advance that could revolutionize bladder cancer treatment, a novel combination of cretostimogene grenadenorepvec and pembrolizumab has shown remarkable efficacy in patients with Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer. Moffitt Cancer Center /articles/moffitt-cancer-center-and-virogen-biotechnology-forge-groundbreaking-partnership-to-accelerate-oncology-and-immunotherapy-innovations/?sc=rsin /articles/moffitt-cancer-center-and-virogen-biotechnology-forge-groundbreaking-partnership-to-accelerate-oncology-and-immunotherapy-innovations/?sc=rsin Fri, 31 May 2024 16:05:40 EST Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Virogen Biotechnology Inc., a clinical-stage biotechnology company, announced a groundbreaking strategic partnership today. This collaboration aims to propel the development of Virogen's cutting-edge fusion protein, VG712 (Resimmune), addressing significant unmet needs in oncology and immunotherapy. Moffitt Cancer Center /articles/moffitt-cancer-center-uses-ai-to-develop-more-personalized-cancer-treatment-strategies/?sc=rsin /articles/moffitt-cancer-center-uses-ai-to-develop-more-personalized-cancer-treatment-strategies/?sc=rsin Tue, 28 May 2024 11:05:08 EST In a study published online ahead of print in Cancer Research, a team of Moffitt Cancer Center researchers introduce a novel framework that leverages deep reinforcement learning to tailor adaptive treatment schedules, potentially doubling the time to progression compared to current standard-of-care protocols. Moffitt Cancer Center /articles/moffitt-initiates-groundbreaking-clinical-trial-with-oncolytic-virus-for-non-small-cell-lung-cancer/?sc=rsin /articles/moffitt-initiates-groundbreaking-clinical-trial-with-oncolytic-virus-for-non-small-cell-lung-cancer/?sc=rsin Tue, 30 Apr 2024 10:05:24 EST Moffitt Cancer Center has launched a pioneering clinical trial for patients with late-stage non-small cell lung cancer whose disease has progressed following initial frontline standard of care immunotherapy that includes an immune checkpoint inhibitor alone or combined with chemotherapy. Moffitt Cancer Center /articles/moffitt-study-suggests-cells-possess-hidden-communication-system/?sc=rsin /articles/moffitt-study-suggests-cells-possess-hidden-communication-system/?sc=rsin Wed, 24 Apr 2024 13:05:19 EST Cells constantly navigate a dynamic environment, facing ever-changing conditions and challenges. But how do cells swiftly adapt to these environmental fluctuations? A new Moffitt Cancer Center study, published in iScience, is answering that question by challenging our understanding of how cells function. A team of researchers suggests that cells possess a previously unknown information processing system that allows them to make rapid decisions independent of their genes. Moffitt Cancer Center /articles/moffitt-researchers-discover-new-therapeutic-target-for-non-small-cell-lung-cancer/?sc=rsin /articles/moffitt-researchers-discover-new-therapeutic-target-for-non-small-cell-lung-cancer/?sc=rsin Thu, 18 Apr 2024 09:05:44 EST A new Moffitt Cancer Center study published in the journal Immunity offers insight into how lung cancer cells evade the protective immune system, potentially opening a door for novel antibody-based immunotherapies. Their study centers on a molecule called Jagged2, which plays a primary role in fueling the aggressiveness and immune evasion capacity of lung cancer. Moffitt Cancer Center /articles/moffitt-treats-first-clinical-trial-patient-with-gamma-delta-car-t-for-bone-metastatic-prostate-cancer/?sc=rsin /articles/moffitt-treats-first-clinical-trial-patient-with-gamma-delta-car-t-for-bone-metastatic-prostate-cancer/?sc=rsin Tue, 16 Apr 2024 13:05:42 EST Moffitt Cancer Center has treated its first patient in an investigator-initiated, phase 1 clinical trial investigating the safety and efficacy of a chimeric antigen receptor T-cell (CAR T) therapy for prostate cancer that has metastasized to the bone. Moffitt Cancer Center /articles/moffitt-cancer-center-to-revolutionize-cancer-care-delivery-using-ai-and-machine-learning-with-nvidia-oracle-and-deloitte/?sc=rsin /articles/moffitt-cancer-center-to-revolutionize-cancer-care-delivery-using-ai-and-machine-learning-with-nvidia-oracle-and-deloitte/?sc=rsin Tue, 02 Apr 2024 08:45:00 EST Moffitt Cancer Center announced today a collaboration with NVIDIA, Oracle and Deloitte* on an initiative aimed at revolutionizing cancer care delivery through advanced artificial intelligence and machine learning technologies. Moffitt Cancer Center /articles/moffitt-s-dr-tiffany-carson-joins-global-cancer-grand-challenges-team-to-tackle-cancer-inequities/?sc=rsin /articles/moffitt-s-dr-tiffany-carson-joins-global-cancer-grand-challenges-team-to-tackle-cancer-inequities/?sc=rsin Wed, 06 Mar 2024 10:05:15 EST An international interdisciplinary team of researchers, including Moffitt Cancer Center's Tiffany Carson, Ph.D., has been selected to receive a Cancer Grand Challenges award. Moffitt Cancer Center /articles/moffitt-researcher-first-in-florida-to-receive-damon-runyon-rachleff-innovation-award/?sc=rsin /articles/moffitt-researcher-first-in-florida-to-receive-damon-runyon-rachleff-innovation-award/?sc=rsin Wed, 06 Mar 2024 09:05:53 EST Alex Jaeger, Ph.D., assistant member of the Molecular Oncology Department at Moffitt Cancer Center, has received a Damon Runyon-Rachleff Innovation Award. He is the first researcher in Florida and at Moffitt to earn this prestigious grant. Moffitt Cancer Center